ABSTRACT: Neuronal inflammation is the characteristic pathologic change of acute neurologic impairment and chronic traumatic encephalopathy after traumatic brain injury (TBI). Inhibiting the excessive inflammatory response is essential for improving the neurologic outcome. To clarify the regulatory mechanism of microglial exosomes on neuronal inflammation in TBI, we focused on studying the impact of microglial exosomal miRNAs on injured neurons in this research. We used a repetitive (r)TBI mouse model and harvested the injured brain extracts from the acute to the chronic phase of TBI to treat cultured BV2 microglia in vitro. The microglial exosomes were collected for miRNA microarray analysis, which showed that the expression level of miR-124-3p increased most apparently in the miRNAs. We found that miR-124-3p promoted the anti-inflamed M2 polarization in microglia, and microglial exosomal miR-124-3p inhibited neuronal inflammation in scratch-injured neurons. Further, the mammalian target of rapamycin (mTOR) signaling was implicated as being involved in the regulation of miR-124-3p by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses. Using the mTOR activator MHY1485 we confirmed that the inhibitory effect of exosomal miR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling. PDE4B was predicted to be the target gene of miR-124-3p by pathway analysis. We proved that it was directly targeted by miR-124-3p with a luciferase reporter assay. Using a PDE4B overexpressed lentivirus transfection system, we suggested that miR-124-3p suppressed the activity of mTOR signaling mainly through inhibiting the expression of PDE4B. In addition, exosomal miR-124-3p promoted neurite outgrowth after scratch injury, characterized by an increase on the number of neurite branches and total neurite length, and a decreased expression on RhoA and neurodegenerative proteins [Ab-peptide and p-Tau]. It also improved the neurologic outcome and inhibited neuroinflammation in mice with rTBI. Taken together, increased miR-124-3p in microglial exosomes after TBI can inhibit neuronal inflammation and contribute to neurite outgrowth via their transfer into neurons. miR-124-3p exerted these effects by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Therefore, miR-124-3p could be a promising therapeutic target for interventions of neuronal inflammation after TBI. miRNAs manipulated microglial exosomes may provide a novel therapy for TBI and other neurologic diseases.-Huang, S., Ge, X., Yu, J., Han, Z., Yin, Z., Li, Y., Chen, F., Wang, H., Zhang, J., Lei, P. Increased miR-124-3p in microglial exosomes following traumatic brain injury inhibits neuronal inflammation and contributes to neurite outgrowth via their transfer into neurons. FASEB J. 32, 000-000 (2018). www.fasebj.org
Traumatic brain injury (TBI) is the most common cause of injury-induced death and long-term disability worldwide, especially in children and young adults (1) . Approximately 10 million people sustain new TBIs each year, with an estimated overall cost of ;U.S. $406 billion (2) . With the acceleration of urbanization, the increase in traffic accidents, and the frequent occurrence of local wars, the incidence of TBI continues to increase rapidly; it will be the third leading contributor to the disease burden by 2020 (3) .
Pathologic development in injured brain after TBI can be divided into 2 phases. The primary insult causes parenchymal damage, intracerebral hemorrhage, and axonal shearing. After that, a series of pathologic events, including inflammation, oxidative stress, metabolic disorder, and cell death in the brain, are induced within hours to days (4) . They interact with each other and lead to secondary brain damage, which is an expansion of the primary insult into the surrounding tissue, manifested by neural damage, local blood supply impairment, blood-brain barrier damage, and pericontusional brain swelling. The inflammatory response plays a significant role in this process. If not properly controlled, its development can aggravate secondary brain damage, which gives rise to progressive neurodegeneration, intracranial hypertension, brain edema, and even brain hernia that result in poor neurologic prognosis (5) . As a pathologic characteristic in the injured brain, the inflammatory response is present throughout the acute and chronic phases of TBI and even lasts for years in patients with a history of repetitive brain trauma that leads to the progressive degenerative disease, chronic traumatic encephalopathy (6, 7) . Although the inflammatory response in an organism has a protective effect as a natural defense reaction, the often excessive production of proinflammatory cytokines appears to become an important driving force for pathologic progression that leads to tissue damage. Thus, inhibiting the excessive inflammatory response is essential for improving neurologic outcome after TBI (8) .
Serving as the macrophage in the CNS, microglia are the key cells in regulating the immunoinflammatory response to maintain homeostasis in the brain. After a TBI, quiescent glial cells of multiple types become rapidly activated and migrate to sites surrounding the injury. During the process, activated microglia generate and release inflammatory mediators, which recruit peripheral immune cells, including neutrophils, lymphocytes, and macrophages into the brain via the damaged blood-brain barrier. These cells and inflammatory mediators act on the surrounding neurons and sensitize them, to enable long-term degenerative processes (9) . Microglia are adept at exhibiting an M1 proinflammatory phenotype, as ensues immediately after TBI, or an M2 anti-inflammatory phenotype that could release various growth factors for repairing the damaged tissue (10) . Thus, microglia exert a double-edged sword effect on the inflammatory response after TBI. Inducing a rapid transition of M1 to M2 microglia after the initiation of the healing process or promoting the M2 polarization from quiescent microglia could suppress excessive inflammatory response in brain and improve the neurologic outcome.
The effect of existing clinical therapeutic methods on controlling the inflammatory response after TBI has not been determined for lack of support from evidencebased medicine. Glucocorticoids have been widely used in controlling cerebral edema and neural inflammation after TBI since their introduction in the 1960s. However, the Medical Research Council (London, United Kingdom) clinical trial, Corticosteroid Randomisation After Significant Head Injury (CRASH), conducted in more than 40 countries and involving 10,008 patients indicated that corticosteroids have no therapeutic effect on patients with TBI regardless of the administration time after injury (11) . Erythropoietin and progesterone have been shown to inhibit the inflammatory response and improve neurologic outcome after TBI in experimental animals. However, phase III clinical trials failed to show a therapeutic effect in patients with TBI (12) (13) (14) . In addition, other drugs with similar functions, including glyburide (NCT01454154), minocycline (NCT01058395), NNZ-2566-a synthetic analog of neuron pharmaceuticals (NCT00805818, NCT01366820)-atorvastatin (NCT02024373), and rosuvastatin (NCT00990028) are still in early clinical trials or finished trials without published results (15, 16) . The stem cell therapy, represented by multipotent mesenchymal stromal cell (MSC) transplantation, could suppress neural inflammation (17) and improve functional recovery after TBI (NCT02028104). Problems of ethics and biosafety have long been concerns that limit its development and further clinical application. Immunotherapy has been a new hotspot for research over the past decade. Immunomodulatory agents, including fingolimod, thymosin b4, peroxisome proliferator-activated receptors agonists (such as rosiglitazone and pioglitazone), the IL-1 receptor antagonist and cell cycle inhibitor flavopiridol have been confirmed to inhibit the inflammatory response after TBI, through inhibiting overactivation of microglia or promoting M2 polarization. However, all of these drugs are in preclinical studies (15, 16, 18) . Consequently, it is important to further explore new strategies for alleviating the inflammatory response in the brain after TBI.
Exosomes are small vesicles with a diameter of 40-100 nm that are liberated from cells into the extracellular space. They interact with other cells at the cell surface via a specific receptor or by mixing of their cargos with cellular contents after endocytosis. The cargos of exosomes mainly include proteins and nucleic acids, which make them a variety of biochemical potential. Thus, research into the formation, cargo loading, trafficking, functioning, and clinical application of exosomes has increased considerably in recent years (19) . Exosomes can express characteristic biomarkers on their membrane that identify the signature of their original cell and the cellular address of where they are to be delivered. In addition, they have a lipid bilayer structure that makes them convenient for long-time storage and allows them to get through the blood-brain barrier easily while protecting their enveloped molecules. For these reasons, the application of exosomes to diagnosis and treatment, especially in neurologic diseases, has broad possibilities (20) .
In our earlier work, we identified the characteristics of the immunoinflammatory response in the brain after TBI induced by a repetitive (r)TBI model that leads to obvious neurologic impairment (21) (22) (23) . Based on these findings, we designed this research to study the impact of microglial exosomal miRNAs on injured neurons, to clarify the regulative mechanism of microglial exosomes on neuronal inflammation in TBI. The results are expected to provide insights for developing novel therapeutic strategies for inhibiting inflammatory response after TBI using miRNA-manipulated microglial exosomes.
MATERIALS AND METHODS
All experimental procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA) and approved by the Tianjin Medical University Animal Care and Use Committee.
Controlled cortical impact-induced rTBI model
To study the impact of microglial exosomes on neurite outgrowth after TBI, an rTBI model that could lead to obvious neurologic impairment with neuroinflammation in injured brain of experimental animals was used as previously reported (21) . Adult male C57BL/6 mice (aged 10-12 wk, weighing 20-25 g) were purchased from the Chinese Academy of Military Science (Beijing, China). The mice were anesthetized with 4.6% isoflurane. They were then positioned in a stereotaxic device by using ear bars. After an 8.0-mm midline scalp incision, a 3.0-mm craniotomy was performed centrally over the right parietal bone. The impounder tip of the injury device (eCCI, model 6.3; American Instruments, Richmond, VA, USA) was then extended to its full impact distance, positioned on the surface of the exposed dura mater and reset to affect its surface. The controlled cortical impact was applied by an impactor at a velocity of 3.6 m/s and a deformation depth of 1.2 mm. Repetitive injury was induced for 4 times with 24-h intervals (21) . Any mice with a herniation of the dura mater were eliminated from the group (24) . After each surgery, the mice were placed in a well-ventilated cage at 37°C until they regained consciousness. Control mice underwent the same procedures except for the cortical impact (sham surgery). To determine the degree of brain injury, hematoxylin and eosin staining was performed on brain sections at 3 d after the last rTBI.
Preparation of brain extracts
To obtain brain extracts, the animals were euthanized at 3, 7, 14, 21, or 28 d after the last brain injury (n = 6/group). As described elsewhere (25) , the mice were anesthetized and euthanized by transcardiac perfusion with cold PBS. The brains were dissected on ice, and the injured hemispheres were isolated. Brain tissue from each time point was homogenized by adding neurobasal medium containing 2% B27 and 1% glutamine (Thermo Fisher Scientific) at a concentration of 100 mg/ml. The homogenate was centrifuged at 12,000 g for 20 min at 4°C. The supernatant from brain tissue extracts was collected and stored at 280°C.
BV2 microglia culture and treatment with rTBI brain extracts BV2 microglial cells were purchased from China Infrastructure of Cell Line Resources (Beijing, China). For the experiments, cells were seeded into 6-well plates at a density of 5 3 10 5 /cm 2 , and cultured in DMEM/F12 culture medium containing 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin (Thermo Fisher Scientific) at 37°C. The purity of cultured microglia was determined by immunofluorescence staining of Iba-1 (a microglia biomarker).
Before treatment with the brain extracts, the microglia were washed twice with PBS and cultured with neurobasal medium without FBS. The brain extracts of rTBI or control mice was added to the culture medium at a ratio of 1:10 (extracts/culture medium). After 24 h, the medium containing the brain extracts was removed, and the microglia were washed twice with PBS to avoid any influence of FBS on the exosomes. Microglia were cultured for another 48 h in serum-free neurobasal medium before subsequent isolation of exosomes (25) .
Microglial exosome isolation and identification
The supernatant of microglia culture medium was collected into 50 ml polypropylene tubes, and centrifuged at 300 g for 10 min at 4°C to remove the free cells. The supernatant was then transferred into a fresh centrifuge tube. It was spun at 2000 g for 10 min at 4°C to remove cell debris and spun again at 10,000 g for 30 min at 4°C to further remove the cell particles. Next, the supernatant was filtered through a 0.22 mm filter (Millipore-Sigma) to remove dead cells and particles larger than 200 nm. After that, ultracentrifugation was performed at 100,000 g for 70 min at 4°C to collect the exosomes. The supernatant was discarded, and the pellets were stored at 4°C temporarily (,24 h) for further experiments.
For exosome identification, transmission electron microscopy (TEM, HT7700; Hitachi, Tokyo, Japan) was used observe the morphology of particles in the pellets. In brief, the pellets were diluted in distilled water (1 mg/ml) and mixed with same amount of 4% paraformaldehyde. Twenty microliters of the sample was added onto a glow-discharged, carbon-coated formvar film that attached to a metal specimen grid. The grid was incubated with 50 ml 1% glutaraldehyde for 5 min at room temperature, and washed 8 times with 100 ml distilled water (2 min each time). After it was dried for 30 min with filter paper, an equal volume of 10% uranyl acetate was added to the grid for 5 min at room temperature, followed by 50 ml methyl cellulose-uranyl acetate (5 ml 4% uranyl acetate and 45 ml 2% methyl cellulose) for 10 min at 4°C. After blotting the excess solution, the sample was dried and examined by TEM. In addition, size distribution of particles in the pellets was measured and analyzed with the Nano Particle Tracking and Zeta Potential Distribution Analyzer (Particle Metrix, Meerbusch, Germany) according to the manufacturer's instructions. Biomarkers for exosomes including CD9, CD63, and Hsp70, were detected with Western blot analysis.
miRNA microarray analysis miRNA microarray analysis was performed by GeneChem (Shanghai, China). The samples were divided into 6 groups of exosomes derived from microglia treated with sham TBI mouse brain (sham) (28 d ). The quality and integrity of the RNA extracted from the exosomes were evaluated first. Next, 200 ng total RNA was labeled with the GeneChip 39 IVT Express Kit (Thermo Fisher Scientific) and hybridized to the GeneChip miRNA 3.0 Array (Thermo Fisher Scientific), which covered 1188 mouse mature miRNAs and 889 pre-miRNAs. RNA molecules were then polyadenylated, followed by a ligation step with a biotin-labeled DNA molecule attached. The labeled RNA was finally washed and stained in the GeneChip Fluidics Station 450, and scanned in the GeneChip Scanner 3000 (Thermo Fisher Scientific). To validate the results of miRNA microarray, real-time PCR was performed to detect the expression level of miR-124-3p in microglia and their exosomes from each sample.
Target prediction and bioinformatics analysis
For the dysregulated miRNAs detected by miRNA microarray, target predication was performed with miRanda (http://www. microrna.org/microrna/home.do), TargetScan (http://www.targetscan. org/), and miRDB (http://mirdb.org/miRDB/). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed with Gene Set Enrichment Analysis software (http://www.broadinstitute.org/gsea/index.jsp) (26) . The miRNA-mRNA pairs simultaneously predicted by the 3 algorithms were considered to be target relationship pairs. The intersection of predicted target genes of miR-124-3p and immunoinflammatory response-related genes was worked out with Ingenuity Pathway Analysis (Qiagen, Hilden, Germany). The genetic interaction network of miR-124-3p was built by PathArray (Qiagen).
MiR-124-3p mimic transfection
To investigate the function of miR-124-3p, miR-124-3p mimic (sequence: 59-UAAGGCACGCGGUGAAUGCCCA-39; GenePharma, Shanghai, China) was transfected into microglia as we described (27) (28) (29) . In brief, the miR-21-3p mimic was diluted to a final concentration of 20 mM. Next, 5 ml miR-21-3p mimic was combined with an equal volume of Lipofectamine-3000 (Thermo Fisher Scientific) in 500 ml serum-free DMEM/F12 and incubated for 20 min at room temperature. This transfection solution was added to the culture plates, which had been washed twice with PBS. After 48 h of transfection, the miR-124-3p-up-regulated exosomes were harvested from the culture medium supernatant. To evaluate transfection efficacy, real-time PCR was performed to detect the change in level of miR-124-3p in microglia and their exosomes.
Flow cytometry
To study the impact of miR-124-3p on microglial polarization, flow cytometry was performed to detect the percentage of M2 microphages in cultured microglia after 48 h of miR-124-3p mimic transfection. In brief, single-cell suspensions of microglia were costained for CD11b (microglia biomarker) conjugated with PE-Cy7 (0.25 mg/test; BioLegend, San Diego, CA, USA) and CD206 (M2 microglia biomarker) conjugated with FITC (0.5 mg/test; BioLegend) for 45 min at room temperature according to the manufacturer's instructions. Samples were analyzed with the FACSAria III flow cytometer (BD Biosciences, San Jose, CA, USA). Subsequent data analysis was performed with FlowJo software v.7.6.1 (Ashland, OR, USA).
Primary culture of cortical neurons
Primary cortical neurons were obtained from brains of 1-d-old C57BL/6 mice. As we reported (27, 28) , the mice were euthanized by cervical dislocation, and the neonatal brain was removed and fragmented in Dulbecco-Hanks' solution (Thermo Fisher Scientific). The meninges, blood vessels, and subcortical tissues were carefully stripped, and the cerebral cortex was minced into 1 mm 3 fragments. The tissue was then digested in 0.25% trypsin EDTA and 100 ng/ml DNAmerase I for 20 min at 37°C. The isolated cells was resuspended by same amount of DMEM/F12 containing 10% FBS, 100 U/ml penicillin, and 100 mg/ml streptomycin, and seeded into 6-well plates precoated with poly-D-lysine (Millipore-Sigma) at a density of 5 3 10 5 /well. After 4 h, the neurobasal medium containing 10% FBS, 2% B27, and 1% glutamine was applied as the culture medium. Neurons were cultured for 7 d, after which the scratch injury and exosomal treatment was performed. The purity of primarily cultured neurons was determined by immunofluorescence staining of microtubule-associated protein (MAP)-2, a neuron biomarker.
Establishment of a neuronal scratch-injury model and treatment of microglial exosomes
To study the impact of microglial exosomes on neurons after TBI in vitro, a scratch injury model was used as we reported (27) . Confluent cultured neurons were scratched across the cell surface (both vertically and horizontally with a 4 mm space between each line) using a 10-ml pipette tip, and detached cells were removed by washing with neurobasal medium.
The cells were randomly assigned into 4 groups: uninjured neurons (control), injured neurons (Injury), injured neurons treated with normal exosome (I+EXO), and injured neurons treated with miR-124-3p-up-regulated exosomes (I+EXO-124). Before exosomal treatment, the neurons were washed twice with PBS and transferred to serum-free neurobasal medium. Medium containing 3 3 10 8 normal exosomes or miR-124-3p-upregulated exosomes was added to the injured neurons (30) . To evaluate the transfer efficiency of miR-124-3p via exosomes, real-time PCR was performed to detect the expression level of miR-124-3p in each group after 72 h.
ELISA
To evaluate the inflammatory response in injured neurons, the cell culture medium was gathered at 72 h after scratch injury and exosomal treatment. ELISA of inflammatory mediators, including TNF-a, IL-1b, IL-6, and IL-10, was performed according to the manufacturer's instructions (R&D Systems, Minneapolis, MN, USA).
In addition, to determine the regulative effect of miR-124-3p on inflammatory response via mammalian target of rapamycin (mTOR) signaling, the expression level of the previouslymentioned inflammatory mediators in injured neurons treated with miR-124-3p-up-regulated exosomes and the mTOR activator were further detected. For these cells, 1 mM MHY1485, a selective mTOR activator (Selleckchem, Houston, TX, USA) (31), was added to the culture medium together with the miR-124-3p-up-regulated exosomes.
Luciferase reporter assay
To verify whether miR-124-3p directly targeted PDE4B mRNA in neurons, luciferase reporter assay was performed as described in Zhou et al. (32) . Luciferase reporter constructs were made by ligating PDE4B 39UTR fragments (;400 bp) containing the predicted binding sites into the luciferase reporter vector pGL3. PCR was performed to amplify a fragment containing PDE4B 39UTR. The primers used for PCR amplifications were as follows (33): forward: 59-AAGCAAGACCAGGAAGCAAA-39, and reverse: 59-GCTGCCCAAGAAAGAAGGAAGA-39.
The product was digested with the XbaI enzyme and ligated with the XbaI-treated pGL3-control vector containing the SV40 promoter. The pGL3-PDE4B-39UTR construct, which contained the potential binding site for miR-124-3p in the PDE4B 39UTR (TargetScan, http://www.targetscan.org/vert_71/), was amplified by PCR from mouse genomic DNA and inserted into the pGL3 control vector (Promega, Madison, WI, USA), using the XbaI site immediately downstream from the stop codon of luciferase in the reporter gene vector. The mutant type of luciferase reporter was generated from the wild-type (WT) luciferase reporter by deleting the binding site for miR-124-3p.
For the reporter assay, neurons were cultured in 96-well plates. The WT or Mut PDE4B-39UTR was cotransfected with 200 pmol miR-124-3p mimic or scrambled oligonucleotides (GenePharma) in neurons with Lipofectamine-3000 (Thermo Fisher Scientific). After 48 h of incubation, the cells were harvested and the luciferase activity was measured with a dual-luciferase reporter system (Promega) referring to the manufacturer's instructions.
Lentivirus transfection
To determine the regulative effect of miR-124-3p on mTOR signaling through targeting PDE4B, a recombinant lentivirus that overexpresses PDE4B was purchased from GenePharma, and transfected into neurons according to the manufacturer's instructions. Scratch injury followed by treatment with miR-124-3p-up-regulated exosomes was performed, and the expression levels of p-4E-BP1 and p-P70S6K were detected by Western blot analysis after 72 h.
In vitro neurite outgrowth assay
Immunofluorescence staining of neuron-specific bIII-tubulin (Tuj1) was performed on injured neurons at 72 h after scratch injury and exosomal treatment. bIII-tubulin + cells were digitized under a 320 objective with a 3-CCD color video camera (DXC-970MD; Sony, Tokyo, Japan) with an immunofluorescence microscope (IX81; Olympus, Tokyo, Japan) and was quantified with the NIS-Elements BR analysis system (Nikon, Tokyo, Japan), which includes measurements of the number and length of branches. At least 60 bIII-tubulin + cells, distributed in 9 random fields per well with triple wells per group, were measured (34). All measurements were performed by an investigator who was blinded to the experiment.
Overexpression of RhoA and neurodegenerative proteins [such as Ab-peptide (APP) and p-Tau] are detrimental to neurite outgrowth (35, 36) . The expression levels of these proteins in neurons were detected by Western blot analysis at 72 h after scratch injury and exosomal treatment.
To investigate whether rTBI-increased miR-124-3p in microglial exosomes transfers to neurons and affects neurite outgrowth, the injured neurons were transfected with the miR-124-3p mimic for 12 h, followed by rinsing with PBS and transfection with miR-124-3p inhibitor (sequence: 59-GGCAUUCACCGC-GUGCCUUA-39; GenePharma) for another 12 h. During the procedure, we observed the changes on neuronal branches continuously in vitro using hopping probe ion conductance microscopy (HPICM) (37) . In brief, the SH01 scan head (Ionscope, Melbourn, United Kingdom) with a nanopipette was placed on the inverted TiU microscope (Nikon). The ICnano controller (Ionscope) managed the positioning and hopping of the nanopipette by 2 PIHera Piezo (100 mm, P-621.2C; Physik Instrumente, Cranfield, United Kingdom) and a LISA piezo (25 mm, P-753.21C; Physik Instrumente). An external Axon Multi Clamp700B amplifier (Molecular Devices, Sunnyvale, CA, USA) provided a +200 mV DC voltage between the nanopipette electrode and the bath electrode and monitored the ion current between the nanopipette tip and cell surface. When the nanopipette tip approached to the neuron membrane, a 0.4% reduction of reference DC currents was set to keep the pipette away from the cell surface. The time needed to scan an area of 80 mm 2 with a typical resolution of 256 3 256 pixels was ;20-30 min. The primary topography data were processed and analyzed with SICM Image Viewer software (Ionscope).
In vivo neurologic outcome and neuroinflammation assay
To study the impact of increased miR-124-3p in microglial exosomes on neurologic outcome and neuroinflammation after TBI, in vivo experiments were performed. The mice were randomly divided into 5 groups: sham surgery (sham), rTBI+PBS (rTBI), rTBI+untransfected microglial exosomes (rTBI+EXO), rTBI +miR-124-3p-up-regulated microglial exosomes (rTBI+EXO-124 + ), and rTBI+miR-124-3p-down-regulated microglial exosomes (rTBI+EXO-124
2 ). miR-124-3p mimic/inhibitor was first transfected into cultured microglia. Then, exosomes generated from these miR-124-3p-up-regulated or -down-regulated cells or nontransfected microglia were harvested and administered intravenously via tail vein to rTBI mice (30 mg total protein of exosome precipitate in 200 ml PBS/mice) at 1 h after the first time of injury (38) . The Morris Water Maze test was performed to evaluate neurologic outcome after TBI, as previously reported (38, 39) . The spatial acquisition trial was performed in the daylight period on 28-32 DPI, and the reference memory probe trial was conducted 1 d after the last spatial acquisition training (d 33). The entire procedure in the pool was monitored by a tracking system (Ethovision 3.0; Noldus Information Technology, Wageningen, The Netherlands) to record the latency time to reach the platform, swim speed, and swim path. From the data, mean values were calculated for each parameter in every learning session. The latency time to reach the submerged platform (d [28] [29] [30] [31] [32] and the time spent in the goal quadrant (d 33) were measured as the indicators of learning ability. In addition, rTBI mice in the above treatment groups were euthanized at 35 DPI, and the expression levels of TNF-a, IL-1b, IL-6, and IL-10 in the injured hemisphere were measured with real-time PCR.
Immunofluorescence staining
The cells were fixed in 4% PFA for 15 min at room temperature, followed by treating with 3% BSA for 30 min at 37°C, to block nonspecific staining. They were then incubated overnight at 4°C with primary antibodies: Iba-1 (1:200), MAP-2 (1:200), and bIIItubulin (1:200; all from Abcam, Cambridge, United Kingdom). The next day, they were rinsed with PBS, and then incubated for 1 h at room temperature with secondary Abs. The nuclei were counterstained with DAPI (Abcam).
Real time PCR
Total RNA was extracted from the cultured microglia, microglial exosomes, and the injured hemispheres of brain tissue with Trizol reagent (Thermo Fisher Scientific). The RNA concentration and quality were evaluated by Nanodrop Spectrophotometer (ND-2000; Thermo Fisher Scientific). cDNA generation and quantitative RT-PCR were performed with the Hairpin-it miR-124-3p/mRNA RT-PCR Quantitation kit (GenePharma) with corresponding primers (Table 1) according to the manufacturer's instructions. U6 served as the internal control for miR-21, and GAPDH was used as the internal control for TNF-a, IL-1b, IL-6, and IL-10. The C t was acquired using the CFX Connect RT-PCR system (Bio-Rad, Hercules, CA USA). The data were analyzed with the 2 2DDCt formula.
Western blot analysis
The SDS/PAGE and immunoblot analysis were performed at 72 h after scratch injury and exosomal treatment. An 8% SDSacrylamide gel was used for detecting APP (1:1000; Cell Signaling Technology, Danvers, MA, USA). SDS-polyacrylamide gel (10%) was used for detecting Hsp70 (1:1000; Abcam), p-P70S6K (1:1000), PDE4B (1:1000; ), and p-Tau (1:1000; all from Cell Signaling Technology). SDS-polyacrylamide gels (12%) were used for detecting CD9 (1:2000) and CD63 (1:1000; both from Abcam Inc.); and p-4E-BP1 (1:1000) and RhoA (1:1000 both from Cell Signaling Technology). GAPDH (1:1000; Cell Signaling Technology) was used as the internal control. For densitometry, the ChemiDoc XRS+ Imaging System (Bio-Rad) was used. Measurement of mean pixel density of each band was performed with Quantity One software (Bio-Rad).
Statistical analysis
All data are results of at least 3 independent experiments and are expressed as means 6 SD. Statistical comparisons were analyzed with 1-way ANOVA followed by least-significant difference post hoc analysis or Student's t test. A value of P , 0.05 was considered significant.
RESULTS
miR-124-3p in BV2 microglia and their exosomes increased after treatment with rTBI mouse brain extracts
To detect the expression profile of miRNAs in microglial exosomes after TBI, pure BV2 microglia were cultured, identified by immunofluorescence staining of Iba-1 (Fig. 1A , Figure 1 . Exosome isolation and identification for BV2 microglia treated with rTBI brain extracts. A) Representative cultured BV2 microglia under a transmission light microscope. B) Immunofluorescence staining of Iba-1 for identifying microglia revealed a pure culture. C ) The TEM image of the microglia-generated particles. The particles were round-shaped with a size range of 40-100 nm.
D) The size distribution of the microglia-generated particles determined by a nano particle tracking analyzer. The peak diameter of the particles was 80.5 6 27.8 nm. E) The immunoblot analysis of characteristic biomarkers for exosomes, including CD9, CD63, and Hsp70. They were all more highly expressed in the microglia-generated particles (par) than in the microglial supernatant (sup). These data suggest that exosomes are the primary component in isolated microglial precipitant. B). We used an rTBI mouse model (Supplemental Fig. 1 
The microglia-generated particles from the culture medium was collected for exosome identification. The TEM image showed the round-shaped morphology of the particles, with a size range of 40-100 nm (Fig. 1C) . The peak diameter of the particles was further detected to be 80.5 6 27.8 nm, with a qNano nanopore-based exosome detection system (Fig. 1D) . In addition, characteristic biomarkers for exosomes, including CD9, CD63, and Hsp70, were highly expressed in the particles (Fig. 1E) . These results suggest that exosomes were the primary component of the isolated microglial precipitant. We collected the total RNA in microglial exosomes and detected the expression profile of miRNAs by using an miRNA microarray ( Fig. 2A and (Fig. 2B, C) . Thus, miR-124-3p was chosen to be the candidate miRNA for our further research.
Increased miR-124-3p in microglia promoted the anti-inflamed M2 polarization
To investigate the function of miR-124-3p, we transfected the miR-124-3p mimic into cultured microglia, which up-regulated the miR-124-3p level (Fig. 3A) . The results of flow cytometry showed an elevation on M2 Mf percentage in microglia treated with miR-124-3p mimic (Fig. 3B, C) . M2 microglia enhance phagocytic activity, reduce production of proinflammatory cytokines, and release anti-inflammatory cytokines that repair damaged tissue (40) . Thus, increased miR-124-3p in microglia promoted anti-inflammatory M2 Figure 2 . Heat map of miRNA microarray analysis for microglial exosomes and real-time PCR validation for miR-124-3p. A) Unsupervised hierarchical clustering of all mouse mature miRNAs and pre-miRNAs for 6 groups of data. The 5 rTBI groups of different time points and the sham group were clustered together in pairs. The colors in the heat map indicated relative expression of miRNAs. Red: a positive value (up-regulation); black: no change; green: a negative value (down regulation). Expression of miR-124-3p increased most apparently among all miRNAs, which were altered more than 2-fold in all rTBI groups. B) The altered miR-124-3p level in microglia and their exosomes from each group was further detected by real-time PCR. miR-124-3p in microglia and their exosomes were both up-regulated in all rTBI groups (n = 6/group). ***P , 0.001 vs. sham group. polarization, which may inhibit neuronal inflammation via their transfer by exosomes.
Increased miR-124-3p in microglial exosomes exerted a protective effect of inhibiting neuronal inflammation
To study the impact of exosomal miR-124-3p on neuronal inflammation after TBI in vitro, we cultured pure cortical neurons identified by immunofluorescence staining of MAP-2 (Fig. 4A, B) , and performed the scratch-injury model (Fig. 4C) . The injured neurons were treated with normal exosomes, or miR-124-3p-up-regulated exosomes that were harvested from microglia transfected with the miR-124-3p mimic (Fig. 4D) . We found that the expression level of miR-124-3p in neurons was increased after scratch injury and was further up-regulated by treatment with miR-124-3p-up-regulated exosomes. No difference was observed between the Injury and I+EXO groups (Fig. 4E) . The expression levels of inflammatory mediators, including TNF-a, IL-1b, IL-6, and IL-10, in the neuron culture medium were detected after scratch injury and exosomal treatment. We found that neuronal inflammation was induced by scratch injury, characterized by an increased expression on proinflammatory cytokines (TNF-a, IL-1b and IL-6) and a decreased expression on anti-inflammatory cytokines (IL-10) (41). Treatment of miR-124-3p-up-regulated exosomes inhibited the inflammatory response by suppressing the expression of TNF-a, IL-1b, and IL-6, and promoting the expression of IL-10 ( Fig. 4F) , suggesting that increased miR-124-3p in Figure 3 . Increased miR-124-3p in microglia promoted anti-inflammatory M2 polarization. The altered miR-124-3p level (A), representative dot spot of flow cytometry (B), and quantitative data of M2 macrophage percentage in cultured microglia after miR-124-3p mimic transfection (C ). Expression of miR-124-3p increased, and M2 polarization was also promoted in the miR-124-3p + group (n = 6/group). ***P , 0.001 vs. control group. microglial exosomes exerted the protective effect of inhibiting neuronal inflammation.
Exosomal miR-124-3p inhibited neuronal inflammation by suppressing the activity of mTOR signaling
To interpret the biological meaning of the level changes on miRNAs in microglial exosomes, we performed GO and KEGG pathway analyses of the commonly dysregulated genes. The top 3 prominent terms were tissue development, regulation of multicellular organismal development, and regulation of transcription from RNA polymerase II promoter in the GO-biologic process analysis ; enzyme binding, ribonucleotide binding, and macromolecular complex binding in GO-molecular function; and cell junction, vacuole, and intravascular vesicle in GO-cellular components analysis (Supplemental Fig. 3A) . For KEGG pathway analysis, pathways in cancer, focal adhesion, and mTOR signaling were overrepresented (Supplemental Fig. 3B ). mTOR signaling plays a significant role in regulating immunoinflammatory response, and its activity was suppressed by miR-124-3p in various diseases, such as Parkinson's disease and hepatocellular carcinoma (42, 43) . Therefore, we put emphasis on studying the roles of the mTOR signaling underlying the regulation of miR-124-3p in neuronal inflammation, to clarify the function and mechanism of microglial exosomes after TBI. 4E-BP1 and P70S6K are downstream targets of mTOR signaling, and their phosphorylation levels represent the signaling activity (44) . Thus, we detected the expression levels of p-4E-BP1 and p-P70S6K in F ) The expression levels of inflammatory mediators in the neuron culture medium after scratch injury and exosomal treatment. Neuronal inflammation was induced by scratch injury, characterized by an increased expression of proinflammatory cytokines (TNF-a, IL-1b, and IL-6) and a decreased expression of anti-inflammatory cytokines (IL-10). Treatment of miR-124-3p-up-regulated exosomes inhibited the inflammatory response by suppressing the expression of TNF-a, IL-1b, and IL-6 and promoting the expression of IL-10, suggesting that exosomal miR-124-3p inhibited neuronal inflammation after scratch injury (n = 6/group).
# P , 0.05, ### P , 0.001 vs. control group; *P , 0.05, ***P , 0.001 vs. injury group neurons after scratch injury and exosomal treatment. We found that their expressions were increased after scratch injury and were suppressed by treatment of miR-124-3p-up-regulated exosomes (Fig. 5A, B) , suggesting that miR-124-3p suppresses the activity of mTOR signaling in injured neurons. Further, we used the mTOR activator MHY1485 to specifically promote mTOR signaling in injured neurons treated with miR-124-3p-upregulated exosomes. We detected the expression levels of inflammatory mediators in the culture medium, and found that MHY1485 blocked the anti-inflammatory effect of miR-124-3p in injured neurons, represented by increased expression on proinflammatory cytokines (TNF-a, IL-1b, and IL-6) and decreased expression on anti-inflammatory cytokines (IL-10) (Fig. 5C) . Therefore, the inhibitory effect of exosomal miR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling.
Exosomal miR-124-3p suppressed the activity of mTOR signaling through directly targeting PDE4B
To further explore the genes directly targeted by miR-124-3p that regulate mTOR signaling, we took the intersection of predicted target genes of miR-124-3p and immunoinflammatory response-related genes and built a genetic interaction network of miR-124-3p. From this, 20 potential target genes of miR-124-3p were preliminarily selected (Fig. 6) . Subsequently, we performed a search on PubMed (http://www.ncbi.nlm.nih. gov/pubmed/) using the query "predicted gene name" AND mTOR. We found that PDE4B was the only qualified gene that correlated with mTOR signaling and was targeted by miR-124-3p (33, 45) .
To verify whether miR-124-3p directly targeted PDE4B mRNA, we first detected the expression level change on PDE4B in neurons after scratch injury and exosomal treatment. We found that its expression increased after scratch injury and was suppressed by miR-124-3p-upregulated exosomes, suggesting that miR-124-3p inhibits the expression of PDE4B in injured neurons (Fig. 7A, B) . Then, we searched for the potential binding site in miR-124-3p for PDE4B 39UTR using TargetScan (Fig. 7C) , and performed the luciferase reporter assay after cotransfecting cultured neurons with PDE4B 39UTR constructs, containing the putative miR-124 binding site with either miR-124-3p mimics or scrambled oligonucleotides. We found that miR-124-3p inhibited the luciferase activity of the WT, but not the Mut 39UTR, reporter construct (Fig.  7D) . The results indicated that miR-124-3p directly targeted PDE4B and down-regulated its expression by binding the 39UTR sites. To determine the regulatory effect of miR-124-3p on mTOR signaling through targeting PDE4B, we transfected a recombinant lentivirus that overexpressed PDE4B in cultured neurons (PDE4B+) and detected the activity of mTOR signaling after scratch injury and exosomal treatment. We found that overexpression of PDE4B blocked the suppressive effect of miR-124-3p on mTOR signaling, represented by an increased expression of p-4E-BP1 and p-P70S6K in the PDE4B+ group. In addition, there was no difference between the Injury group (injured neurons without Figure 5 . Exosomal miR-124-3p inhibited neuronal inflammation by suppressing the activity of mTOR signaling. The immunoblot (A) and quantitative (B) data of p-4E-BP1 and p-P70S6K in neurons after scratch injury and exosomal treatment. Their expression was increased after scratch injury and was suppressed by miR-124-3p-up-regulated exosomes, suggesting that miR-124-3p suppresses the activity of mTOR signaling (n = 6/group).
## P , 0.01 vs. control group; **P , 0.01 vs. injury group. C ) The expression levels of inflammatory mediators in the culture medium were detected in the 3 groups of neurons: injured neurons (injury group), injured neurons treated with miR-124-3p-up-regulated exosomes (I+EXO-124), and injured neurons treated with miR-124-3p-upregulated exosomes and the mTOR activator (MHY1485). Compared with the I+EXO-124 group, the MHY1485 group represented an increased expression on proinflammatory cytokines (TNF-a, IL-1b, and IL-6) and a decreased expression of anti-inflammatory cytokines (IL-10), suggesting that MHY1485 blocks the anti-inflammatory effect of miR-124-3p in injured neurons. Thus, the inhibitory effect of exosomal miR-124-3p on neuronal inflammation was exerted by suppressing the activity of mTOR signaling (n = 6/group).
# P , 0.05 vs. injury group; *P , 0.05 vs. I+EXO-124 group. treatment) and the PDE4B+ group. These results indicate that exosomal miR-124-3p suppresses the activity of mTOR signaling mainly through directly targeting PDE4B.
Exosomal miR-124-3p promotes neurite outgrowth after scratch injury Neuronal inflammation can lead to neurodegeneration that hinders neurite outgrowth (46) . To study the impact of anti-inflammatory exosomal miR-124-3p on neurite outgrowth, we quantified the number of neurite branches and total neurite length after scratch injury and exosomal treatment using immunofluorescence staining of neuron-specific bIII-tubulin (Fig. 8A) . We found that scratch injury induced a decrease in the number of neurite branches and total neurite length, but that miR-124-3p-up-regulated exosomes reversed the change (Fig. 8B, C) . In addition, we detected the expression levels of RhoA and the neurodegenerative proteins APP and p-Tau, which are detrimental to neurite outgrowth (35, 36) . Western blot data showed that their expression increased after scratch injury and was suppressed by miR-124-3p-up-regulated exosomes (Fig. 8D, E) . Further, continuous HPICM topological scanning was performed to observe the changes in neuronal branches after successive transfection of miR-124-3p mimic and miR-124-3p inhibitor in injured neurons. We found that the number of neurite branches and total neurite length decreased after scratch injury. They then increased after transfection with the miR-124-3p mimic for 12 h and decreased again after transfection with miR-124-3p inhibitor for another 12 h. Thus, the increase in miR-124-3p level in injured neurons enhanced neurite outgrowth. These results suggest that exosomal miR-124-3p promotes neurite outgrowth after scratch injury.
Increased miR-124-3p in microglial exosomes improve the neurologic outcome and inhibit neuroinflammation in rTBI mice
To study the impact of increased miR-124-3p in microglial exosomes on neurologic outcome after TBI, the Morris Water Maze test was performed in rTBI mice at 28-33 DPI. This spatial-acquisition trial was conducted to test spatial learning ability. Escape latency, which represents the capability to navigate from a start location to a submerged platform, gradually decreased from 28 to 32 DPI, suggesting that a spatial memory was established (repeated-measures ANOVA; F (4, 120) = 639.5; P , 0.001). The probe trial was performed at 33 DPI to test the retrograde reference memory, where more time spent in the goal quadrant demonstrates better memory. We found that rTBI resulted in obvious neurologic impairment manifested by increased escape latency and decreased time spent in the goal quadrant. Compared with the rTBI group, the rTBI+EXO-124 + group displayed a decrease in escape latency and an increase in time spent in the goal quadrant, whereas reversed results were observed in the rTBI+EXO-124 2 group (Fig. 9A, B) . No difference in swim speed was observed among the groups, indicating that the different performance was not related to motor impairments. These data suggest that increased miR-124-3p in microglial exosomes improve the neurologic outcome after TBI.
The influence of increased miR-124-3p in microglial exosomes on neuroinflammation was also evaluated by detecting the expression levels of inflammatory mediators in the injured hemisphere of rTBI mice. We found that rTBI Figure 6 . The genetic interaction network of miR-124-3p. There were 20 immunoinflammatory responserelated genes that were predicted to be the target genes of miR-124-3p, among which PDE4B was the only qualified gene that correlated with mTOR signaling.
led to neuroinflammation in injured brain, characterized by increased expression of proinflammatory cytokines (TNF-a, IL-1, and IL-6) and a decreased expression on antiinflammatory cytokines (IL-10). Compared with the rTBI group, treatment with miR-124-3p-up-regulated exosomes inhibited the inflammatory response by suppressing the expression of TNF-a, IL-1b, and IL-6 and promoting the expression of IL-10, whereas intervention with miR-124-3p-down-regulated exosomes exerted a reversed effect that exacerbated the neuroinflammation (Fig. 9C) . Thus, increased miR-124-3p in microglial exosomes could exert a protective effect of inhibiting neuroinflammation after TBI.
DISCUSSION
In the present study, we demonstrated for the first time that the miR-124-3p level in microglial exosomes increased from the acute to the chronic phase of TBI. The increased miR-124-3p in microglia significantly promoted antiinflammatory M2 polarization; inhibited neuronal inflammation, and promoted the neurite outgrowth in scratch-injured neurons via their transfer by exosomes; and improved the neurologic outcome and inhibited neuroinflammation in rTBI mice. In addition, these effects of miR-124-3p was exerted by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Our results suggest that miR-124-3p would be a promising therapeutic target for intervention in neuronal inflammation after TBI. Intravenous administration of miRNAs manipulated microglial exosomes may represent a novel therapeutic approach for treatment of TBI and other neurologic diseases.
Brain-derived exosome is a significant component of the signaling network in the CNS, which regulates the pathologic change in various neurologic diseases. Exosomes derived from microglia resemble those released by The relative luciferase activity of the WT and mut reporter constructs, which were cotransfected with either the miR-124-3p mimic or scrambled oligonucleotides. Data are presented as the ratio of luciferase activity from the scrambled oligonucleotides vs. miR-124-3p mimic-transfected neurons. miR-124-3p inhibited the luciferase activity of the WT, but not the mut 39UTR reporter construct. miR-124-3p directly targeted PDE4B and down-regulated its expression by binding the 39UTR sites.
## P , 0.01 vs. control group. The immunoblot (E ) and quantitative (F ) data of expression levels of p-4E-BP1 and p-P70S6K were detected in the 3 groups of neurons: injured neurons (injury group), injured neurons treated with miR-124-3p-up-regulated exosomes (I+EXO-124), and PDE4B-overexpressing injured neurons treated with miR-124-3p-up-regulated exosomes (PDE4B+). Compared with the I+EXO-124 group, the PDE4B + group showed an increased expression on p-4E-BP1 and p-P70S6K, suggesting that overexpression of PDE4B blocks the suppressive effect of miR-124-3p on mTOR signaling in injured neurons. There were no differences between the Injury group and the PDE4B + group. Therefore, exosomal miR-124-3p suppressed the activity of mTOR signaling, mainly through directly targeting PDE4B (n = 6/group).
## P , 0.01 vs. injury group; **P , 0.01 vs. I+EXO-124 group.
dendritic cells and B lymphocytes under basal conditions and is consistent with their roles in the immune system (47) . Microglial exosomes can function as an ancillary source of energy for neurons during synaptic activity by loading acetate, which is transported by exosomal containment (48) . In addition, microglial exosomes are released in response to WNT3A, which is internalized and in turn stimulates the release of exosomes containing WNT3A. WNTs are signaling factors that have been implicated in several neurodegenerative diseases, such as Alzheimer disease (AD), suggesting that microglial exosomes regulate their pathologic development (49) .
Microglial exosomes can also be influenced by neurotransmitters. Stimulation of their 5-hydroxytryptamine receptors leads to the release of exosomes containing insulin-degrading enzyme, which can degrade APP, a neurotoxic peptide in AD. This result may explain the phenomenon that the increased level of 5-hydroxytryptamine is associated with a decreased APP level in AD mouse brain (50) . In addition, microglial exosomes contribute to the propagation of Tau in AD, which greatly determines the neurologic prognosis (51) . From this evidence, we conclude that microglial exosomes may play a significant role in regulating neurologic Their expression increased after scratch injury and was suppressed by miR-124-3p-up-regulated exosomes. F ) Continuous HPICM topological scanning of control and injured neurons in vitro. The number of neurite branches and total neurite length decreased after scratch injury, increased after transfection with the miR-124-3p mimic for 12 h, and decreased again after transfection with miR-124-3p inhibitor for another 12 h. Thus, the increase in miR-124-3p level in injured neurons enhanced neurite outgrowth. These results suggest that exosomal miR-124-3p promotes neurite outgrowth after scratch injury (n = 6/ group).
## functional recovery. Although microglial exosomes have been widely studied in chronic neurologic diseases, especially in neurodegenerative diseases, little attention has been paid to their roles in acute neurologic diseases, such as TBI. Therefore, we focused on studying the impact of microglial exosomal miRNAs on injured neurons in this research. Using the rTBI mouse model, we harvested the brain extracts, which were added to the cultured BV2 microglia, to imitate the microenvironment of injured brain on in vitro-cultured cells. Thus, the microglial exosomes under TBI condition could be separately collected from brain-derived exosomes for further investigation of their roles in TBI. miRNA is abundant in exosome containment, which regulates gene expression in other cells through the release and uptake of exosomes. We found that miR-124-3p was increased in exosomes from microglia that were treated with brain extracts of 3, 7, 14, 21, and 28 DPI. miR-124-3p has been identified in surveillant microglia and anti-inflamatory M2 microglia. It is revealed to switch cell polarization from the M1 to the M2 phenotype in various subsets of monocyte cells and microglia (52) . Down-regulation of its expression level is an indicator of neuroinflammation in various diseases, such as experimental autoimmune encephalomyelitis (53) and intracerebral hemorrhage (54) . In the present research, we confirmed that miR-124-3p promoted anti-inflammatory M2 polarization in microglia and exert an anti-inflammatory effect on injured neurons via their transfer by microglial exosomes. Thus, the findings suggest that the increased miR-124-3p in microglial exosomes exert a protective effect in injured brain after TBI.
mTOR signaling is a well-known regulator of the immunoinflammatory response. Recent studies have demonstrated that mTOR signaling is involved in the regulation of immune reactions in many neurologic diseases, including brain trauma and AD (55, 56) . Inhibition of mTOR signaling reduces the deleterious actions of microglia and promotes anti-inflammatory M2 polarization (57, 58) . In accordance with previous research on Parkinson's disease, our present study of TBI demonstrated that suppressing the activity of mTOR signaling inhibited neuronal inflammation, and this effect was promoted by miR-124-3p (42) . These findings further proved that the miR-124-3p in microglial exosomes can be transferred into neurons.
In microglial exosomes in TBI conditions, we performed microarray using GeneChip miRNA 3.0 Array (Affymetrix), and bioinfomatics analysis using Ingenuity Pathway Figure 9 . Increased miR-124-3p in microglial exosomes improved neurologic outcome and inhibited neuroinflammation in rTBI mice. The escape latency in the spatial acquisition trial (A) and the time spent in the goal quadrant in the probe trial (B) of the Morris Water Maze test. rTBI resulted in obvious neurologic impairment manifested by increased escape latency and decreased time spent in the goal quadrant, which was improved by treatment with miR-124-3p-up-regulated exosomes, but was exacerbated by miR-124-3p-down-regulated exosome intervention. C ) The expression levels of inflammatory mediators in the injured hemisphere of rTBI mice. rTBI led to neuroinflammation in injured brain, characterized by increased expression of proinflammatory cytokines (TNF-a, IL-1b, and IL-6) and a decreased expression on anti-inflammatory cytokines (IL-10). The inflammatory response was inhibited in the rTBI+EXO-124 + group, but was promoted in the rTBI+EXO-124 2 group (n = 6/group). These results suggest that increased miR-124-3p in microglial exosomes would improve the neurologic outcome and inhibit neuroinflammation after TBI. # P , 0.05,Analysis. The results suggest that PDE4B is the only qualified gene that correlates with mTOR signaling and is targeted by miR-124-3p (33, 45) . The family of PDE4 enzymes is an underexploited therapeutic target for neurologic diseases, as there are no amino acid sequence differences in the active site among the PDE4 subtypes. PDE4B is one of the subtypes that are specifically expressed in brain. Its inhibition has the potential to alleviate neuroinflammation through reducing proinflammatory cytokine production by microglia (59) . In AD, mice deficient in PDE4B display decrease on expression of proinflammatory TNF-a in response to inflammatory stimulus, and PDE4B negative modulator can blunt microglia production of TNF-a, suggesting that PDE4B could be a therapeutic target for inhibiting neuroinflammation (60, 61) . Our research on TBI confirmed these results, and provided a novel method to suppress PDE4B expression by inducing miR-124-3p-upregulated microglial exosomes in injured neurons. Neuronal inflammation can lead to neurodegeneration that hinders neurite outgrowth, and inhibition of inflammatory response increases the expression and functioning of neurotrophic factors and thus promotes neurite outgrowth (46) . Overexpression of RhoA and neurodegenerative proteins are detrimental to neurite outgrowth. Their expression levels represent the degree of neuronal damage (35, 36) . In the current research, we suggested that microglial exosomal miR-124-3p inhibited neuronal inflammation via suppressing the activity of mTOR signaling by targeting PDE4B. We also found that applying exosomal miR-124-3p to injured neurons, or direct transfection of miR-124-3p into the cells both promoted neurite outgrowth characterized by an increase on the number of neurite branches and total neurite length. These results indicate that microglial exosomal miR-124-3p can promote neurite outgrowth, at least partly by inhibiting neuronal inflammation, which is consistent with the results of a previous report that miR-124-3p disinhibits neurite outgrowth in an inflammatory environment (62) . In addition, increased miR-124-3p in microglial exosomes improved the neurologic outcome and inhibited neuroinflammation in rTBI mice. Therefore, based on the findings from in vitro and in vivo experiments, we can draw the conclusion that increased miR-124-3p in microglia after TBI can inhibit neuronal inflammation and contributes to neurite outgrowth via their transfer by exosomes into neurons.
For future study, we are performing in vivo experiments to clarify the therapeutic effect and mechanism of miR-124-3p-upregulated microglial exosomes on neurite outgrowth after TBI. In addition, a series of studies on MSC-derived exosomes for TBI treatment have been reported recently, suggesting that they could effectively improve the neurologic outcome by promoting endogenous angiogenesis and neurogenesis, while attenuating neural inflammation (30, 63, 64) . Thus, up-regulating the miR-124-3p level in MSC-derived exosomes could be a therapeutic approach for TBI. We will evaluate its effect on controlling neural inflammation and improving neurologic outcome and compare the results to the therapeutic effect of miR-124-3p-upregulated microglial exosomes. The roles of exosomes derived from other cells in the brain, such as neurons and astrocytes, should be further elucidated, especially their impact on the inflammatory response after TBI. This research expands the understanding of the function and mechanism of microglial exosomes in TBI and opens an avenue to novel therapeutic strategies for inhibiting inflammatory response after TBI and other neurologic diseases using miRNA-manipulated microglial exosomes.
CONCLUSIONS
The major discovery of our research is that the miR-124-3p level in microglial exosomes is increased apparently from acute phase to chronic phase of TBI. Increased miR-124-3p in microglia inhibits neuronal inflammation and contributes to neurite outgrowth via its transfer by exosomes into neurons. It can also improve the neurologic outcome and inhibits neuroinflammation in rTBI mice. These effects of miR-124-3p are exerted by targeting PDE4B, thus inhibiting the activity of mTOR signaling. Therefore, miR-124-3p may be a promising therapeutic target for interventions of neuronal inflammation after TBI. miRNA-manipulated microglial exosomes may provide a novel therapy for TBI and other neurologic diseases. 
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